Analysts/Institutional Investor Meet/Con. Call Updates

August 18, 2026 Listing Department Code: 532321 BSE LIMITED P J Towers, Dalal Street, Mumbai–400 001 Listing Department Code: ZYDUSLIFE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, C/1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai–400 051 Sub: Transcript of the post results earnings call held on August 11, 2026, pursuant to regulations 30 and 46(2)(oa) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the Listing Regulations”) Dear Sir / Madam, Pursuant to regulations 30 and 46(2)(oa) of the Listing Regulations, please find attached the transcript of the Company’s Q1 FY27 post results earnings call held on August 11, 2026. Please find the same in order. Thanking you, Yours faithfully, For, Zydus Lifesciences Limited Dhaval N. Soni Company Secretary and Compliance Officer Membership No. FCS7063 Encl.: As above “Zydus Lifesciences Limited Q1 FY27 Post Results Earnings Call” August 11, 2026 MANAGEMENT: DR. SHARVIL PATEL - MANAGING DIRECTOR, ZYDUS LIFESCIENCES LIMITED MR. GANESH NAYAK - DIRECTOR, ZYDUS LIFESCIENCES LIMITED MR. TUSHAR SHROFF – CHIEF FINANCIAL OFFICER, ZYDUS LIFESCIENCES LIMITED MR. ARVIND BOTHRA - HEAD, INVESTOR RELATIONS, ZYDUS LIFESCIENCES LIMITED MR. ALOK GARG - MD OFFICE, ZYDUS LIFESCIENCES LIMITED 1 of 19 Moderator: Ladies and gentlemen, good day and welcome to Zydus Lifesciences’ earning conference call for the first quarter of FY27. Please note, all participants' lines will be in listen-only mode, and there will be an opportunity for you to ask questions after management's opening remarks. Should you need any assistance during the conference call, please raise your hand from the ‘Participant’ tab on the screen. While asking questions, request you to please identify yourself and your company. Please note, this conference is being recorded. I now hand over the call to Mr. Ganesh Nayak, Director at Zydus Lifesciences. Thank you and over to you, Sir. Mr. Ganesh Nayak: Good evening, ladies and gentlemen. It is my pleasure to welcome you all to our post-results teleconference for the first quarter ended June 30, 2026. For today's call, we have with us, Dr. Sharvil Patel, Managing Director, Mr. Tushar Shroff, Chief Financial Officer, Mr. Arvind Bothra, Head of Investor Relations and Mr. Alok Garg from the Managing Director's Office. To begin with, let me talk about the key developments during the quarter. I am happy to report that we commenced FY27 with strong double-digit growth, building on the formidable base of FY26. This performance reflects the sustained momentum across all our key businesses, each of which contributed meaningfully to the overall performance during the quarter. With this, first of all, let me walk you through the financial performance for the quarter under review: We registered consolidated revenues of ₹ 80.2 billion, up 22% on a year-on-year basis. On the operating profitability front as well, our performance was robust with an EBITDA margin of 24.1%. Consequently, EBITDA for the quarter stood at ₹ 19.3 billion while net profit for the quarter stood at ₹ 9.4 billion. Our net debt to EBITDA ratio stood at 0.7 times as on 30th of June, 2026. Now, let me take you through the operating highlights for the first quarter of FY27 for our key business segments. In the Pharmaceutical space, In India, our branded formulations business sustained market outperformance with a strong 20% year-on-year growth during the quarter. This business has, in fact, outperformed the market growth consistently over the last three financial years. Growth during the quarter was broad-based as we grew faster than the market in super-specialty, chronic, as well as acute segments. In terms of therapy performance, the business grew faster than the market in cardiology, diabetology, gynecology, anti-infectives, pain management, and in the super- specialty areas of oncology and nephrology. Our ranking improved in key 2 of 19 therapies of cardiology, diabetology, and pain management while on the super- specialty front, we continued to retain leadership position in the oncology therapy. Our large innovative brands led by Lipaglyn® continue to strengthen their market standing and improve their rankings quarter after quarter, underscoring the impact of our innovation on improved patient outcomes. Contribution of chronic and sub-chronic portfolio has increased consistently over the last several years and stood at 54.2% as per AWACS MAT June 2026, an improvement of 360 basis points over the last 4 years. International markets formulations business has delivered strong growth during the last several quarters and has established itself as a formidable growth pillar for the company. The business sustained the growth momentum during the quarter and posted revenues of ₹ 9.7 billion with a year-on-year growth of 34%. The growth was led by strong demand-driven performance across markets and supported by focused execution. North America business, comprising of the US and Canada, exhibited resilience with revenues of ₹ 31 billion during the quarter, up 5% quarter-on-quarter. The base US Business continued to gain share driven by sustained volume expansion, supplemented by new product launches. On the US generics front, we filed 5 ANDAs, received 9 approvals (including 4 tentative approvals), and launched 11 new products during the quarter. Our US specialty business achieved two important milestones during the quarter. First, we launched NufymcoTM Injection, which is Ranibizumab, our first biosimilar in the US market, marking a meaningful expansion of our specialty capabilities and laying the foundation for future participation in the growing biosimilar segment. Second, we completed the acquisition of Assertio Holdings, significantly strengthening our commercial capabilities, portfolio breadth, and market access in the US specialty space. These milestones underscore our continued focus on building a robust specialty platform in the US and advancing our transition towards a more differentiated, innovation-led business model. In Canada, we received 2 ANDS approvals and launched 2 new products during the quarter. Our Consumer Wellness business recorded revenues of ₹ 14.3 billion, up 67% year-on-year. Within this, the international business, including the Comfort Click portfolio, delivered a like-to-like growth of 25%, while the domestic business grew 5% year-on-year. Within the domestic portfolio, skin & hair care and food & nutrition continued their strong momentum, delivering growth of 35% and 16% respectively. Seasonal brands, however, de-grew primarily due to the softer summer season. In the medical devices space, the business registered revenues of ₹ 2.8 billion during the quarter. We are investing in enhancing our capabilities in the focused therapies, which offer long-term growth potential to create differentiated value. 3 of 19 On the operations front, our injectable manufacturing facility at Zydus Biotech Park recently received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification, following a GMP surveillance inspection conducted in April’2026 and May’2026. During the quarter, we entered into a joint venture agreement with Sunshine Healthcare to establish a pharmaceutical manufacturing facility in Sri Lanka to strengthen local production and reduce import dependence for the country. Now, this concludes the business review. I would now request Dr. Sharvil Patel to take you through the key drivers across businesses as well as initiatives in our innovation program. Thank you. Dr. Sharvil Patel: Thank you, Mr. Nayak, and good evening, ladies and gentlemen. It's a pleasure to have you all here today on our call. FY27 is off to a great start with a strong performance across the key businesses. More importantly, we continue to advance our transformation into an innovation-led organization. The share of our branded portfolio in the total revenues has steadily increased ov [Showing first 8,000 characters — download PDF for full document]